Cytodyn Inc (CYDY)

[fred198484]

The top line interim PE data is the first hump and it would be very surprising if CYDY does not get over that one easily. The second hump is the financing and the positive data will help them get over that one too. The issue with this hump is how that will impact current shareholders. The company will likely make it over this hump but will shareholders get hammered in the process? It is hard to see how they won't get hurt and they could get trampled, depending on how the company decides to proceed. The third hump is just all the FDA filing stuff that needs to get done and that just takes time. They need to get a manufacturing and marketing partner as well and get the FDA to define how PRO 140 will be labeled. This is only the beginning. It will be a long time before the company is cash flow positive - think mid 2020 at the earliest.